Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,841 companies covered, latest filing Oct 23.

  • $29.6B bought by 1412 insiders at 808 companies
  • $28.4B sold by 2631 insiders outside a trading plan
  • $21.2B sold by 1966 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past 3 months, each insider's filings added up.

  1. REBNReborn Coffee
    Jung Jae LimCEO
    131,387 shares at $180,000.00 Jul 14 New stake
    $23.6B
  2. RSGRepublic Services
    Cascade Investment, L.l.c.10% owner, +1 joint filer
    6,254,462 shares at $220.69 Aug 10–Sep 11, 12 filings +5.6% to stake
    $1.4B
  3. NMMNavios Maritime Partners
    Angeliki FrangouSee Remarks
    15,333 shares at $55,256.14 Jul 23–Aug 12, 5 filings +0.3% to stake
    $847M
  4. LENLennar
    Berkshire Hathaway Inc.10% owner, +1 joint filer
    7,502,276 shares at $79.35 Sep 17–Oct 2, 4 filings 3 superinvestors bought in Q2
    $595M
  5. JEFJefferies
    Sumitomo Mitsui Financial Group, Inc.Director
    5,906,542 shares at $54.86 Jul 15 +222% to stake 1 superinvestor bought in Q2
    $324M
  6. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    8,431,139 shares at $34.32 Sep 9–Oct 21, 30 filings +6.9% to stake 2 superinvestors bought in Q2
    $289M
  7. MAIRMadison Air Solutions
    Ernesto Bertarelli10% owner, +1 joint filer
    8,770,524 shares at $24.97 Aug 25 +23% to stake
    $219M
  8. GPIGroup 1 Automotive
    Conifer Management, L.L.C.10% owner
    720,030 shares at $260.08 Sep 1–30, 6 filings +60% to stake 2 superinvestors bought in Q2
    $187M
  9. KODKodiak Sciences
    Baker Bros. Advisors LPDirector, +5 joint filers
    1,941,755 shares at $80.85 Sep 28–29, 3 filings +11% to stake 1 superinvestor sold in Q2
    $157M
  10. SAFXXCF Global
    EEME Energy SPV I, LLC10% owner
    119M shares at $1.19 Oct 16 +109% to stake
    $142M

Biggest sales

Past 3 months, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    183,400 shares at $42,790.60 Aug 21–Oct 20, 6 filings Planned sale (10b5-1)
    $7.8B
  2. FANGDiamondback Energy
    SGF FANG Holdings, LP10% owner, +1 joint filer
    18.2M shares at $205.26 Sep 16, 2 filings 22% of stake
    $3.7B
  3. MDLNMedline
    GIC Private Ltd10% owner, +2 joint filers
    32.9M shares at $35.06 Aug 5–Oct 8, 5 filings
    $1.2B
  4. BIRKBirkenstock
    James Michael ChuDirector
    28.1M shares at $39.18 Aug 17 28% of stake
    $1.1B
  5. CHYMChime Financial
    DST Global Advisors Ltd10% owner, +9 joint filers
    32.5M shares at $32.93 Aug 6–Sep 14, 20 filings 99% of stake
    $1.1B
  6. NVDANvidia
    Mark A StevensDirector
    4,236,740 shares at $223.43 Aug 31–Sep 18, 3 filings 81% of stake
    $947M
  7. JMKEJersey Mike's Subs
    Submarine Buyer LLC10% owner, +6 joint filers
    32.3M shares at $21.85 Jul 31–Aug 25, 2 filings 15% of stake
    $705M
  8. AURAurora Innovation
    Uber Technologies, Inc10% owner
    101M shares at $6.45 Aug 17–Sep 15, 2 filings 39% of stake
    $654M
  9. ALHAlliance Laundry
    Bdt Capital Partners, LLCDirector, +6 joint filers
    25.9M shares at $22.74 Aug 20 18% of stake
    $590M
  10. ANETArista Networks
    Jayshree UllalCEO
    2,465,344 shares at $206.71 Aug 5–Oct 9, 9 filings Planned sale (10b5-1)
    $510M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 6 insiders, $1.7M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

    Latest buy Oct 23 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Joel L. Frank Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

IMNM insider trades

Every open-market buy and sale in IMNM, one row per filing, newest first

IMNM page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Jack Higgins Chief Scientific Officer
    IMNMImmunome
    Planned sale
    $334K 13,200 shares at $25.32 17% of stake
    Traded Sep 11 Filed Sep 15
    ↗
  2. Isaac Barchas Director
    IMNMImmunome
    Planned sale
    $2.2M 83,464 shares at $26.35
    Traded Aug 10–12 Filed Aug 12
    ↗
  3. Isaac Barchas Director
    IMNMImmunome
    Planned sale
    $940K 36,088 shares at $26.06 33% of stake
    Traded Aug 6–7 Filed Aug 10
    ↗
  4. Kinney Horn Chief Business Officer
    IMNMImmunome
    Planned sale
    $2.3M 90,616 shares at $25.09 100% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  5. Kinney Horn Chief Business Officer
    IMNMImmunome
    Planned sale
    $27K 1,092 shares at $25.00 100% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  6. Robert Lechleider Chief Medical Officer
    IMNMImmunome
    Planned sale
    $1.2M 55,000 shares at $22.62 78% of stake
    Traded Jul 2 Filed Jul 7
    ↗
  7. Isaac Barchas Director
    IMNMImmunome
    Planned sale
    $2.4M 100,000 shares at $24.13 48% of stake
    Traded Jul 6–7 Filed Jul 7
    ↗
  8. Isaac Barchas Director
    IMNMImmunome
    Planned sale
    $4.4M 201,050 shares at $21.85 49% of stake
    Traded Jun 30–Jul 2 Filed Jul 2
    ↗
  9. Robert Lechleider Chief Medical Officer
    IMNMImmunome
    Planned sale
    $1.1M 55,000 shares at $19.85 78% of stake
    Traded Jun 25 Filed Jun 29
    ↗
  10. Max Rosett CFO
    IMNMImmunome
    Planned sale
    $1.1M 60,000 shares at $18.23 53% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  11. Jean Jacques Bienaime Director
    IMNMImmunome
    Sale
    $204K 10,500 shares at $19.41 24% of stake
    Traded Jun 5 Filed Jun 9
    ↗
  12. Jean Jacques Bienaime Director
    IMNMImmunome
    Buy
    $204K 10,500 shares at $19.45 +32% to stake
    Traded Jun 5 Filed Jun 9
    ↗
  13. Jean Jacques Bienaime Director
    IMNMImmunome
    Buy
    $104K 5,000 shares at $20.70 +13% to stake
    Traded May 15 Filed May 19
    ↗
  14. Max Rosett CFO
    IMNMImmunome
    Planned sale
    $1.4M 65,000 shares at $21.92 55% of stake
    Traded Apr 2 Filed Apr 3
    ↗
  15. Jack Higgins Chief Scientific Officer
    IMNMImmunome
    Planned sale
    $204K 9,438 shares at $21.64 30% of stake
    Traded Apr 2 Filed Apr 3
    ↗
  16. Clay B Siegall CEO
    IMNMImmunome
    Buy
    $501K 25,450 shares at $19.67 +3.8% to stake
    Traded Mar 27 Filed Mar 31
    ↗
  17. Philip Wagenheim Director
    IMNMImmunome
    Sale
    $1.3M 65,000 shares at $20.55 16% of stake
    Traded Mar 20–23 Filed Mar 23
    ↗
  18. Jean Jacques Bienaime Director
    IMNMImmunome
    Buy
    $44K 2,000 shares at $21.84 +5.5% to stake
    Traded Mar 10–11 Filed Mar 12
    ↗
  19. Clay B Siegall CEO
    IMNMImmunome
    Buy
    $100K 4,729 shares at $21.15 +0.7% to stake
    Traded Dec 30, 2025 Filed Dec 30, 2025
    ↗
  20. Isaac Barchas Director
    IMNMImmunome
    Planned sale
    $8.3M 383,200 shares at $21.74 16% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
    ↗
  21. Philip Tsai Chief Technical Officer
    IMNMImmunome
    Buy
    $205K 10,000 shares at $20.49 +30% to stake
    Traded Dec 19, 2025 Filed Dec 22, 2025
    ↗
  22. Clay B Siegall CEO
    IMNMImmunome
    Buy
    $149K 7,278 shares at $20.48 +0.9% to stake
    Traded Dec 19, 2025 Filed Dec 22, 2025
    ↗
  23. Clay B Siegall CEO
    IMNMImmunome
    Buy
    $1M 46,511 shares at $21.50 +5.8% to stake
    Traded Dec 18, 2025 Filed Dec 18, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,841 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.